Company Insights

SGHT customer relationships

Explore interactive graphBrowse insights index
SGHT customer relationship map

Sight Sciences (SGHT): Customer relationships that unlock reimbursement and revenue pathways

Sight Sciences designs and sells ophthalmic devices—principally the OMNI and SION systems for glaucoma and the TearCare platform for dry eye—monetizing through point‑of‑sale device sales to surgical facilities and eye care practitioners, plus procedure‑driven pricing where reimbursement is secured. Revenue is heavily driven by Surgical Glaucoma products sold in the U.S., with TearCare historically sold on a cash‑pay basis while the company secures formal CPT pricing and payer coverage. For a concise view of how these customer-facing dynamics affect partner and payor engagement, see our homepage: https://nullexposure.com/.

How Sight Sciences generates cash and where customers sit in the revenue chain

Sight Sciences recognizes revenue at the point in time when control of products transfers to customers, reflecting a transactional contracting posture: devices are sold to ASCs, hospital outpatient departments and eye care professionals, and the company uses a combination of direct sales teams and distributors to reach buyers. The business is concentrated by product segment—Surgical Glaucoma accounted for roughly 95% of total revenue for 2024—while customer concentration is low, with no single customer representing 10% or more of revenue in 2023 or 2024. Financials show $77.4M revenue TTM with negative net income metrics and meaningful margin pressure, underscoring the strategic importance of establishing sustainable reimbursement for procedure‑based sales.

Named payors and pricing partners in the record

The dataset captures two payor/pricing entities that have taken concrete steps relevant to TearCare reimbursement. Below are concise, source‑backed summaries of each relationship.

First Coast Service Options

First Coast Service Options established pricing for CPT code 0563T—the code associated with the TearCare procedure—alongside other Medicare Administrative Contractors in the fourth quarter reported for FY2026. This action represents a direct payer pricing decision that converts a historically cash‑pay procedure into a billable service under Medicare frameworks. See the FY2026 earnings call transcript coverage on InsiderMonkey: https://www.insidermonkey.com/blog/sight-sciences-inc-nasdaqsght-q4-2025-earnings-call-transcript-1710579/.

Novitas Solutions

Novitas Solutions is likewise named among the MACs that set pricing for CPT 0563T in the same FY2026 quarter, aligning multiple regional Medicare contractors on reimbursement for TearCare and creating a clearer billing pathway for providers. The same earnings call transcript documents this coordination across MACs: https://www.insidermonkey.com/blog/sight-sciences-inc-nasdaqsght-q4-2025-earnings-call-transcript-1710579/.

Key takeaway: coordinated pricing by MACs such as Novitas and First Coast for CPT 0563T materially advances TearCare’s commercialization profile by reducing the out‑of‑pocket barrier for patients and creating a scalable route for procedure reimbursement.

Operating constraints and what they signal about the commercial model

Sight Sciences’ public disclosures and the extracted constraints outline a set of operational truths that investors must incorporate into forecasts and risk assessments.

  • Contracting posture: spot, transactional sales. Revenue recognition language and historical sales of TearCare on a cash‑pay basis indicate a predominantly point‑of‑sale commercial model rather than long‑term recurring contracts. This structure creates revenue volatility tied to procedure adoption and supplier inventories rather than contract amortization.
  • Geographic concentration: U.S. centric with selective EMEA presence. The company reports approximately 95% of revenue from U.S. customers, with direct operations in the U.K. and Germany and distributor arrangements across Europe. Geographic concentration elevates single‑market policy and reimbursement risk while leaving upside tied to international expansion execution.
  • Customer concentration: dispersed buyers but product concentration. No customer exceeded 10% of revenue in 2023–2024, signaling low buyer concentration; however, 95% of revenue derives from the Surgical Glaucoma segment, making the business product‑concentrated and therefore sensitive to competitive displacement or procedural shifts.
  • Relationship roles: multi‑channel sales motion. The company sells directly to surgical facilities and ECPs, and uses distributors and sales representatives; the combination positions Sight Sciences to scale but requires consistent field investment and distributor management.
  • Maturity: commercialization plus reimbursement transition. TearCare’s historical cash‑pay model and the recent MAC pricing actions illustrate a product in transition from limited direct‑pay adoption to insurer‑reimbursed procedure status—this converts commercial progress into potentially durable revenue growth only if provider uptake follows.

These constraints are company‑level signals derived from the firm’s disclosures; none of the constraints explicitly assign a particular constraint to a named payor relationship.

Investment implications: what the relationships and constraints mean for valuation

Sight Sciences sits at a classic med‑tech inflection: commercial traction depends less on one large buyer than on payer acceptance, provider adoption, and sustained sales execution. The recent MAC pricing steps materially lower the commercialization hurdle for TearCare and convert an out‑of‑pocket procedure into a reimbursable service, which can increase addressable volume without requiring changes to the device economics.

Risks to model:

  • Reimbursement rollout timing and regional heterogeneity remain execution risks despite MAC pricing; provider coding, claims adjudication, and private payor alignment will determine realized payments.
  • Product concentration (95% Surgical Glaucoma) means company revenue is sensitive to competitive launches or changes in surgical practice patterns.
  • Financial profile portrays negative profitability (diluted EPS TTM -0.74) and a history of operating losses, so cash burn and capital access matter for scaling direct sales and distributor networks.

For analysts modeling growth scenarios, incorporate a phased reimbursement uptake curve tied to MAC rollouts and private payor coverages rather than assuming immediate volume multipliers. Additional context and strategic implications are available at our homepage: https://nullexposure.com/.

Actionable next steps for investors and operators

Sight Sciences’ immediate commercial catalyst is reimbursement normalization for TearCare—MAC pricing by Novitas and First Coast is a tangible step that shifts market dynamics. Analysts should:

  • Revisit revenue forecasts to capture incremental procedure volume from Medicare reimbursement and test sensitivity to private‑payor adoption.
  • Monitor unit economics at the facility level once reimbursed payments are in place to validate durability of margins versus cash‑pay sales.
  • Track geographic expansion execution in the U.K. and Germany as a secondary growth path beyond U.S. policy levers.

For deeper coverage modeling and comparable analysis of reimbursement events and customer relationships, visit our resource hub: https://nullexposure.com/.

Bottom line: Sight Sciences operates a transactionally‑driven device business with concentrated product exposure and dispersed customer base; recent MAC pricing actions materially improve TearCare’s commercial runway, but durable upside depends on sustained provider adoption and payor alignment.